Movement Alert｜Madrigal Pharmaceuticals Falls 6.74% in Pre-Market Trading, Q2 Earnings Beat Estimates but Per-Share Loss Widens Year-Over-Year

Market Focus07-30

On July 30, Madrigal Pharmaceuticals fell 6.74% in pre-market trading, trading at $508.12/share, with turnover of $754,800.

The decline came despite the company reporting second-quarter results that exceeded Wall Street expectations on both top and bottom lines. Madrigal posted a net loss of $1.99 per share, beating the analyst consensus estimate of $2.50 by 20.4%, while quarterly product revenue of $364.252 million surpassed the $353.178 million estimate. However, the per-share loss widened 4.74% year-over-year from $(1.90), with total net loss reaching $57.939 million for the quarter.

The company's core product Rezdiffra delivered net sales of $364.3 million, representing 71% year-over-year growth. As of June 30, more than 49,000 patients were on Rezdiffra, more than doubling from the prior-year period. Despite the operational momentum, the stock faced selling pressure as the widening loss trajectory weighed on investor sentiment. Wells Fargo recently initiated coverage with an Outperform rating and a $685 price target.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1173806056?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-30 20:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173806056","market":"us","top_or_hot":-1,"title":"Movement Alert｜Madrigal Pharmaceuticals Falls 6.74% in Pre-Market Trading, Q2 Earnings Beat Estimates but Per-Share Loss Widens Year-Over-Year","media":"Market Focus","content":"<p><p>On July 30, Madrigal Pharmaceuticals fell 6.74% in pre-market trading, trading at $508.12/share, with turnover of $754,800.</p><p>The decline came despite the company reporting second-quarter results that exceeded Wall Street expectations on both top and bottom lines. Madrigal posted a net loss of $1.99 per share, beating the analyst consensus estimate of $2.50 by 20.4%, while quarterly product revenue of $364.252 million surpassed the $353.178 million estimate. However, the per-share loss widened 4.74% year-over-year from $(1.90), with total net loss reaching $57.939 million for the quarter.</p><p>The company's core product Rezdiffra delivered net sales of $364.3 million, representing 71% year-over-year growth. As of June 30, more than 49,000 patients were on Rezdiffra, more than doubling from the prior-year period. Despite the operational momentum, the stock faced selling pressure as the widening loss trajectory weighed on investor sentiment. Wells Fargo recently initiated coverage with an Outperform rating and a $685 price target.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Madrigal Pharmaceuticals Falls 6.74% in Pre-Market Trading, Q2 Earnings Beat Estimates but Per-Share Loss Widens Year-Over-Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Madrigal Pharmaceuticals Falls 6.74% in Pre-Market Trading, Q2 Earnings Beat Estimates but Per-Share Loss Widens Year-Over-Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-30 20:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 30, Madrigal Pharmaceuticals fell 6.74% in pre-market trading, trading at $508.12/share, with turnover of $754,800.</p><p>The decline came despite the company reporting second-quarter results that exceeded Wall Street expectations on both top and bottom lines. Madrigal posted a net loss of $1.99 per share, beating the analyst consensus estimate of $2.50 by 20.4%, while quarterly product revenue of $364.252 million surpassed the $353.178 million estimate. However, the per-share loss widened 4.74% year-over-year from $(1.90), with total net loss reaching $57.939 million for the quarter.</p><p>The company's core product Rezdiffra delivered net sales of $364.3 million, representing 71% year-over-year growth. As of June 30, more than 49,000 patients were on Rezdiffra, more than doubling from the prior-year period. Despite the operational momentum, the stock faced selling pressure as the widening loss trajectory weighed on investor sentiment. Wells Fargo recently initiated coverage with an Outperform rating and a $685 price target.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDGL","symbol_name":"Madrigal Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1173806056","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173806056","pubTimestamp":1785413989,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 30, Madrigal Pharmaceuticals fell 6.74% in pre-market trading, trading at $508.12/share, with turnover of $754,800.The decline came despite the company reporting second-quarter results that...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDGL":"Madrigal Pharmaceuticals, Inc."},"translate_title":"走势警报|牧歌制药盘前交易下跌6.74%，第二季度盈利超出预期，但每股亏损同比扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDGL":1},"content_text":"On July 30, Madrigal Pharmaceuticals fell 6.74% in pre-market trading, trading at $508.12/share, with turnover of $754,800.The decline came despite the company reporting second-quarter results that exceeded Wall Street expectations on both top and bottom lines. Madrigal posted a net loss of $1.99 per share, beating the analyst consensus estimate of $2.50 by 20.4%, while quarterly product revenue of $364.252 million surpassed the $353.178 million estimate. However, the per-share loss widened 4.74% year-over-year from $(1.90), with total net loss reaching $57.939 million for the quarter.The company's core product Rezdiffra delivered net sales of $364.3 million, representing 71% year-over-year growth. As of June 30, more than 49,000 patients were on Rezdiffra, more than doubling from the prior-year period. Despite the operational momentum, the stock faced selling pressure as the widening loss trajectory weighed on investor sentiment. Wells Fargo recently initiated coverage with an Outperform rating and a $685 price target.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1173806056","isCrawlerRequest":true}